US equities |
NVDA $238.55 ▲+1.97% SPCX $167.30 ▲+5.25% MU $1,063.30 ▼-1.08% TSLA $380.32 ▲+2.63% MSFT $525.51 ▲+1.54% SNDK $1,708.85 ▼-0.65% INTC $117.19 ▼-1.80% META $743.00 ▲+2.05%
FinancialContent

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

8.580 +0.350 (+4.25%)
Delayed Quote Updated: 2:30 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 13, 2024 ↗
 
Via Benzinga
News headline image
Preview: DiaMedica Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Recap: DiaMedica Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
DiaMedica Therapeutics Upcoming Conference Participation
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024 ↗
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces $11.8 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024 ↗
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023 ↗
DMAC stock results show that DiaMedica Therapeutics met analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >